IGF1R- and ROR1-Specific Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas Haein Park, PhD, Xin Huang, MD, Joseph Greene, BA,

Slides:

Advertisements

Similar presentations

Xenotransplantation of Human Cord Blood Derived Unrestricted Somatic Stem Cells Rescue the Blistering Phenotype in a Murine Model of Recessive Dystrophic.

Advertisements

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

How to Treat MDS without Stem Cell Transplantation

Assessment of Safety and Efficacy of Peripheral Blood Stem Cell (PBSC) Mobilization with G-CSF in Haploidentical Maternal Donors with Sickle Cell Trait.

A Survival Benefit for Reduced Intensity Allogeneic Transplants from Young Unrelated Donors Compared to Older Sibling Donors Depends on the Graft CD8.

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia Katerina Ancevski,

Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Systematic Anti-Mold Prophylaxis Results in Very Low Incidence of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Targeting CLEC12A with Chimeric Antigen Receptor T Cells Can Overcome the Chemotherapy Refractoriness of Leukemia Stem Cells Saad S. Kenderian, Marco.

Biology of Blood and Marrow Transplantation

Neuroblastoma and Ewing's Sarcoma Associated with ROR1 Expression Can Be Effectively Targeted with NK Cells Modified to Express an Anti ROR1 Chimeric.

Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas Xin Huang, MD, Joseph Greene, BA, James Pao, BA, Erin Mulvey, BA, Sophia X.

TIM-1 Blockade of the Donor Graft Provides Protection Against Lethal Gvhd Bettina P. Iliopoulou, PhD, Katie Hsu, MS, Antonio Pierini, MD, Gordon J. Freeman,

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Previously Treated Germ Cell Tumors: A Single-Center Experience Zachariah DeFilipp,

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia Saad S. Kenderian, MD, Marco Ruella, MD,

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Safety & Efficacy of Liposomal Amphotericin B Followed By Micafungin to Prevent Invasive Fungal Infection in Pediatric Allogeneic Stem Cell Transplantation.

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Claudio Brunstein, MD, PhD, Keli Hippen, Todd E

Distinctions Between Effective and Ineffective AML-Specific Autologous Peripheral Blood (PB) Cytotoxic T-Lymphocytes (CTLs) Rohtesh S. Mehta, MD MPH.

CD33 Directed Chimeric Antigen Receptor T Cell Therapy As a Novel Preparative Regimen Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Hidekazu Itamura, M. D. , Takero Shindo, M. D. , Ph. D

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Graft-Versus-Host Disease Targets Granulosa Cell of Ovarian Follicle and Causes Infertility after Allogeneic Hematopoietic Stem Cell Transplantation

Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Strategy Hideki Nakasone, Mats Remberger, PhD, Lu Tian,

Potential Use of Human Placenta Derived Stem Cell (HPDSCs) As a Novel Stem Cell Source for the Treatment of Recessive Dystrophic Epidermolysis Bullosa.

Discovery of ST2 Inhibitors: From Biomarker to Potential Drug Target in Graft-Versus- Host Disease Chao-Yie Yang, PhD, Jilu Zhang, PhD, Etienne Daguindau,

ROR1-Specific Chimeric Antigen Receptor (CAR) NK Cell Immunotherapy for High Risk Neuroblastomas and Sarcomas Haein Park, Aradhana Awasthi, Janet Ayello,

Rescue of the Mucocutaneous Manifestations in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa (RDEB) By Human Cord Blood Derived Unrestricted.

Infection Prevention - Visitors and the Best of Intentions

Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model Saad S. Kenderian,

Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.

Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.

Robust Donor Chimerism and Engraftment Following Familial Haploidentical (FHI) (CD34 Enriched and T-Cell Addback) Allogeneic Stem Cell Transplantation.

Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse Saad S. Kenderian, David L. Porter,

Myeloid Derived Suppressor Cells (MDSC)-like Acute Myeloid Leukemia (AML) Cells Are Associated with Resistance to Cytotoxic Effects of Autologous (Auto)

Two Partial T Cell Depletion Strategies for Unrelated Donor Peripheral Stem Cell Transplantation are Associated with Excellent Outcomes for Pediatric.

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

Automated Production of Clinical-Grade CMV-Specific T Cells to Implement Immunotherapy at the Bedside Priti Tewari, MD, Pappanaicken R. Kumaresan, PhD,

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

September Mitchell, BSN, MHI, RN, CHTC, OCN, Sarah L

Xenotransplantation of Human Cord Blood Derived Unrestricted Somatic Stem Cells Rescue the Blistering Phenotype in a Murine Model of Recessive Dystrophic.

Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation

Targeting ST2 Alleviates Graft-Versus-Host Disease Mortality and Maintains Graft- Versus-Leukemia Jilu Zhang, PhD, Benjamin Ulrich, Abdulraouf Ramadan,

Renee C. Gresh, DO, E. Anders Kolb, MD, Corinna L

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Blood and Marrow Transplant Handbook

Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.

Combining Dinutuximab with ALT-803 (IL-15 Superagonist) Significantly Improves the Activity of Ex Vivo Expanded Natural Killer Cells Against GD2+ Pediatric.

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Biology of Blood and Marrow Transplantation

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Mammen Chandy Biology of Blood and Marrow Transplantation

Heather A. Himburg, PhD, Liman Zhao, Jenny Kan, John P. Chute, M.D.

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Biology of Blood and Marrow Transplantation

Treatment versus Transplant for Challenging Hematologic Disorders

Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation

Analysis of 402 Cord Blood Units to Assess Factors Influencing Infused Viable CD34+ Cell Dose: The Critical Determinant of Engraftment Duncan Purtill,

In Memoriam: E. Donnall Thomas

CD137 Expression Identifies Leukemia Specific CTL after in Vitro Priming of Cord Blood T Cells Previously Expanded By CD3/CD28 Co-Stimulation Jeyaraj.

Presentation transcript:

IGF1R- and ROR1-Specific Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas Haein Park, PhD, Xin Huang, MD, Joseph Greene, BA, James Pao, BA, Erin Mulvey, BA, Sophia X. Zhou, Deepali Sachdev, PhD, Douglas Yee, MD, Christoph Rader, PhD, Catherine M. Albert, MD, Carl Hamby, PhD, David Loeb, MD, PhD, Mitchell S. Cairo, MD, Xianzheng Zhou, PhD Biology of Blood and Marrow Transplantation Volume 21, Issue 2, Pages S52-S53 (February 2015) DOI: 10.1016/j.bbmt.2014.11.686 Copyright © 2015 Terms and Conditions

Fig 1 In vitro and In vivo anti-sarcoma activity of IGF1R and ROR1 CART cells. (A) Cytotoxicity assays, (B) Anti-sarcoma activity in a systemic model, SaOS2-fflucN cells (7.5x105) were i.v. injected into NSG mice for 5 days, treated with mockH IGF1R CAR (IGZ) and ROR1 CAR (RGZ)T cells (1x107) on day 6 and 9, and imaged for tumor control on day 11, 17, 24, 31 and 38, (C) Survival benefit of CAR T cells in a local sarcoma model, SaOS2-fflucN (3x105) cells were i.p. injected in NOD/SCID mice, untreated or treated with mock, IGF1R CAR (IGZ) and ROR1 CAR (RGZ)T cells on day 3, 5 and 7 and monitored for survival. Biology of Blood and Marrow Transplantation 2015 21, S52-S53DOI: (10.1016/j.bbmt.2014.11.686) Copyright © 2015 Terms and Conditions